{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_references_citation in Reference Text / Citation (approximate match)
Status:
Investigational
Source:
NCT04711837: Phase 3 Interventional Completed Anesthesia
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03459079: Phase 2 Interventional Completed Nonalcoholic Fatty Liver Disease (NAFLD)
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
IVA-337 (LANIFIBRANOR), an indole sulfonamide derivative, is a pan peroxisome proliferator-activated receptor (PPAR) agonist. It is under investigation in Phase 2 clinical trials for non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, and type 2 diabetes.
Status:
Investigational
Source:
NCT04312997: Phase 2 Interventional Completed COVID-19
(2020)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Investigational
Source:
NCT03903549: Phase 1 Interventional Completed Parkinson Disease
(2022)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03709628: Phase 1 Interventional Completed Crohn Disease
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03773133: Phase 1/Phase 2 Interventional Terminated Small Cell Lung Cancer and Breast Cancer
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00004496: Phase 1 Interventional Completed Acute Renal Failure
(1999)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
alpha-MELANOTROPIN (also known as an alpha-melanocyte-stimulating hormone or alpha MSH) is an endogenous melanocortin 1-receptor agonist, which exclusively expressed in cells of the melanocytic lineage. alpha-MELANOTROPIN possesses anti-inflammatory properties and antagonizes proinflammatory mediators, including TNF-alpha, IL-6 and NO, and induces anti-inflammatory cytokine IL-10. alpha-MELANOTROPIN was studied in phase I clinical trial in patients with acute renal failure. In addition, this compound was assigned of orphan designation for the treatment of chronic beryllium disease.
Status:
Investigational
Source:
INN:rintodestrant [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04480710: Phase 2 Interventional Completed NASH - Nonalcoholic Steatohepatitis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
